Brief: Lixte Biotechnology Holdings, Inc. Announces That Enrollment Has Resumed In National Cancer Institute’S Trial To Determine Ability Of Lixte Compound Lb-100 To Enter Recurrent, Malignant Brain Tumors

NOMAD Power Solutions

22/11/2021 17:39

Nov 22 (Reuters) - Lixte Biotechnology Holdings Inc
 LIXT.O :
    * LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT
ENROLLMENT HAS
RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE
ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT
BRAIN TUMORS

Source text for Eikon:  ID:nGNX5JVD86 
Further company coverage:  LIXT.O 

 ((Reuters.Briefs@thomsonreuters.com;))